Lower GI Bleed Admission Order Set: Resuscitation, Colonoscopy Timing, and Management
This order set addresses the acute management of lower gastrointestinal hemorrhage presenting as hematochezia, maroon-colored stool, or melena with a suspected colonic source. Admission is indicated for patients with an Oakland score >8, hemodynamic instability, significant hemoglobin drop, or high-risk comorbidities including active anticoagulant use. The primary goals include rapid hemodynamic stabilization targeting MAP ≥65 mmHg and heart rate <100 bpm, risk stratification using the Oakland score, timely bowel preparation for urgent colonoscopy within 24 hours, and identification of the bleeding source for targeted hemostatic intervention. This protocol applies to general ward, step-down, and ICU settings depending on hemodynamic severity.
Assessment & Monitoring
Acute lower gastrointestinal bleeding requires systematic risk stratification and continuous hemodynamic assessment from the moment of presentation. The Oakland score serves as the primary validated tool for disposition decisions, incorporating age, sex, prior lower GI bleed hospitalization, digital rectal examination findings, heart rate, systolic blood pressure, and hemoglobin level. Patients with a self-limited bleed, no adverse clinical features, and a score of 8 or below can be considered for discharge with outpatient investigation, while those scoring above 8 require inpatient admission with appropriate level of care based on hemodynamic status. Continuous telemetry monitoring is essential for all patients with active bleeding, tachycardia, or hemodynamic instability. Serial hemoglobin measurements every 6 hours during the first 24 hours guide transfusion decisions and detect occult ongoing hemorrhage that may not be clinically apparent from stool output alone. All patients should be maintained on strict bed rest with fall precautions during active bleeding episodes, and nursing should document stool frequency, volume, and color using a standardized grading system to track bleeding trajectory.
Oakland Score Components
| Parameter | Criteria | Points |
|---|---|---|
| Age | ≤39 years: 0 • 40–69 years: 1 • ≥70 years: 2 | 0–2 |
| Sex | Female: 0 • Male: 1 | 0–1 |
| Previous LGIB admission | No: 0 • Yes: 1 | 0–1 |
| DRE findings | No blood: 0 • Blood on exam: 1 | 0–1 |
| Heart rate | <70: 0 • 70–89: 1 • 90–109: 2 • ≥110: 3 | 0–3 |
| Systolic BP | ≥160: 0 • 130–159: 2 • 120–129: 3 • 90–119: 4 • 50–89: 5 | 0–5 |
| Hemoglobin (g/dL) | ≥16.0: 0 • 13.0–15.9: 4 • 11.0–12.9: 8 • 9.0–10.9: 13 • 7.0–8.9: 17 • 3.6–6.9: 22 | 0–22 |
Risk stratification
Acute lower GI bleeding: level of care by severity
Oakland score (age, sex, prior LGIB admission, DRE, heart rate, SBP, hemoglobin) plus hemodynamic status
Oakland score ≤8
- Self-limited bleed with no adverse clinical features
- No other admission criterion, e.g. Hb <10 g/dL, HR >100 or SBP <100 mmHg, anticoagulant or dual antiplatelet therapy
Management
- Can be considered for discharge with outpatient investigation and close follow-up
Oakland score 9–15, hemodynamically stable
Management
- Ward-level admission with serial monitoring
Oakland score ≥16, hemodynamically stable
Management
- High risk: consider step-down or ICU-level care
- Urgent GI consult
Any Oakland score with hemodynamic instability or massive bleeding
Management
- Stabilize before endoscopy; ICU transfer if vasopressors or massive transfusion protocol are needed
- CT angiography if ongoing bleeding is suspected; active extravasation: IR consult for embolization
- Upper endoscopy unless CTA shows a definitive lower GI source
Score >8: admission for observation, resuscitation and inpatient workup including colonoscopy.
Laboratory Orders
Initial laboratory evaluation must be obtained immediately upon presentation to guide resuscitation intensity and identify coagulopathy requiring correction. A type and screen with crossmatch for 2 units of packed red blood cells should be sent on all admitted patients with active bleeding. Serial hemoglobin monitoring every 6 hours during the acute phase enables early detection of ongoing hemorrhage and guides transfusion decisions. Coagulation studies are critical in patients on anticoagulant therapy to determine the need for reversal agents. Lactate measurement provides an objective marker of tissue hypoperfusion and should be trended to assess resuscitation adequacy.
Laboratory Panel Discipline: What Experienced Clinicians Order on Admission
The admission laboratory panel for LGIB extends beyond the reflexive “type and screen plus CBC” pattern that often anchors order sets. The standard admission panel includes complete blood count with platelets and reticulocyte count, basic metabolic panel with magnesium and phosphorus, coagulation profile with PT/INR plus aPTT, type and screen with two units cross-matched if Oakland score is intermediate-to-high, lactate as a perfusion marker, liver enzymes including alkaline phosphatase and total bilirubin (variceal differential plus chronic liver disease screen), and lipase if any concurrent abdominal pain. For patients on direct oral anticoagulants, anti-Xa level for apixaban or rivaroxaban and dilute thrombin time for dabigatran where available — though clinical reversal, suggested for the small subset of patients with a life-threatening LGIB that does not respond to initial resuscitation and cessation of the anticoagulant alone, usually proceeds based on time-since-last-dose rather than waiting for assay return. For patients with melena or hematochezia where upper source has not been excluded, BUN-to-creatinine ratio above 30 raises suspicion for upper GI source and triggers concurrent upper endoscopy planning. Cardiac troponin is reasonable in elderly patients with significant blood loss to detect demand ischemia. Stool studies (C. difficile, ova and parasites, occult blood verification) are typically not urgent and can be deferred to inpatient floor. Group and crossmatch should be repeated every 24 hours during active bleeding because antibody patterns may develop with transfusion exposure.
Medications
Medication management in acute lower GI bleeding focuses on three pillars: hemodynamic stabilization through targeted resuscitation, correction of coagulopathy to facilitate hemostasis, and empiric acid suppression until an upper GI source has been definitively excluded. Since up to 15% of patients presenting with apparent hematochezia actually have a brisk upper GI source, empiric proton pump inhibitor therapy is warranted pending endoscopic evaluation. Anticoagulation reversal decisions must balance the risk of continued hemorrhage against the thrombotic risk of withholding anticoagulants, requiring individualized assessment and often multidisciplinary input from hematology and the primary prescribing team. Tranexamic acid, while studied in GI bleeding, has not demonstrated mortality benefit in the HALT-IT trial and is not routinely recommended. All vasoactive medications and blood products carry high-alert designation requiring independent double-check verification before administration.
Primary Therapy
Dose: Pantoprazole (Protonix) 40 mg IV once daily Grade B
Indication: Empiric acid suppression until upper GI source excluded by EGD or clinical course; continue if concurrent gastric/duodenal pathology identified
Renal adjust: No dose adjustment required for any CrCl level
Monitor: Magnesium level if anticipated use >5 days; transition to PO when tolerating diet
Dose: pRBC 1 unit IV over 1-2 hours per unit
Indication: Hb <7 g/dL (restrictive threshold) or Hb <9 g/dL in patients with CAD, hemodynamic instability, or active ischemic symptoms Grade A
Target: Hb ≥7 g/dL (general) or ≥9 g/dL (CAD/unstable); recheck Hb 1 hour post-transfusion
Monitor: Transfusion reaction vitals q15min × first unit; post-transfusion Hb at 1h and 6h
Dose: Octreotide (Sandostatin) 50 mcg IV bolus, then 50 mcg/hr continuous infusion x 3-5 days Grade B
Indication: Suspected variceal bleed or known portal hypertension/cirrhosis with acute hemorrhage; initiate empirically if variceal source cannot be excluded
Renal adjust: No dose adjustment required; dialysis does not significantly remove octreotide
Monitor: Blood glucose q6h (risk of hypo/hyperglycemia); heart rate (bradycardia); reassess need after endoscopic diagnosis
Anticoagulation Reversal
Dose: Vitamin K (Phytonadione) 10 mg IV over 30 minutes PLUS 4-Factor PCC (KCentra) 25-50 units/kg IV based on INR
Indication: Life-threatening LGIB on warfarin with an INR substantially exceeding the therapeutic range, or with hemodynamic instability (most patients with LGIB on warfarin are unlikely to require reversal); 4-factor PCC is preferred to fresh frozen plasma; routine vitamin K is not suggested, but vitamin K is administered concurrently when 4-factor PCC is given; PCC dose: INR 2–3.9 = 25 units/kg (max 2500 units); INR 4–6 = 35 units/kg (max 3500 units); INR >6 = 50 units/kg (max 5000 units)
Renal adjust: No dose adjustment; caution in severe renal failure due to thrombotic risk
Monitor: INR 30 minutes post-PCC infusion (target <1.5); repeat INR at 6h and 24h; monitor for thromboembolism (DVT, PE, stroke) for 72h post-administration
Dose: Idarucizumab (Praxbind) 5 g IV as two 2.5 g boluses no more than 15 minutes apart Grade A
Indication: Life-threatening LGIB in patients on dabigatran (Pradaxa) that does not respond to initial resuscitation and cessation of the anticoagulant alone; use when available if dabigatran has been taken within the past 24 hours
Renal adjust: No adjustment; idarucizumab is a humanized monoclonal antibody fragment
Monitor: Thrombin time or dilute thrombin time pre- and 2h post-dose to confirm reversal; ecarin clotting time as alternative. Resume anticoagulation 24h after hemostasis if indicated.
Dose: Andexanet alfa (Andexxa) low-dose: 400 mg IV bolus at 30 mg/min then 4 mg/min x 120 min (for rivaroxaban ≤10 mg, apixaban ≤5 mg, or last dose >8h ago). Andexanet alfa high-dose: 800 mg IV bolus then 8 mg/min x 120 min (for rivaroxaban >10 mg or apixaban >5 mg with last dose <8h ago)
Indication: Life-threatening LGIB in patients on rivaroxaban (Xarelto) or apixaban (Eliquis) that does not respond to initial resuscitation and cessation of the anticoagulant alone; use when available if the drug has been taken within the past 24 hours. In a December 18, 2025 safety communication, the FDA stated that it considers the risks of Andexxa (andexanet alfa) to outweigh its benefits and that Andexxa will no longer be manufactured for or sold in the U.S. by AstraZeneca after December 22, 2025.
Renal adjust: No dose adjustment required
Monitor: Boxed warning: arterial and venous thromboembolic events, ischemic events (including myocardial infarction and ischemic stroke), cardiac arrest, and sudden deaths; monitor for thromboembolic events and initiate anticoagulation when medically appropriate, and monitor for symptoms and signs that precede cardiac arrest. Current commercial clinical anti-FXa activity assays are unsuitable for measuring FXa activity following administration of andexanet alfa (erroneously elevated anti-FXa activity levels underestimate its reversal activity); monitor for thromboembolic events for 30 days; 10% thrombosis risk within 30 days
PRN Medications
Dose: Acetaminophen (Tylenol) 1000 mg IV q6h PRN for pain or temperature >38.5 C
Indication: Pain or fever management; preferred analgesic (avoids NSAID-related GI injury and platelet inhibition)
Max: 4000 mg/day (2000 mg/day if hepatic impairment, chronic alcohol use, or weight <50 kg)
Dose: Ondansetron (Zofran) 4 mg IV q6h PRN nausea/vomiting
Indication: Nausea or vomiting, especially during GoLYTELY bowel preparation
Max: 16 mg/day IV; monitor QTc if concurrent QT-prolonging medications
Prophylaxis
Dose: Enoxaparin (Lovenox) 40 mg SC daily, begin after hemostasis confirmed x 24h Grade B
Type: VTE prophylaxis — initiate only after no active bleeding for ≥24h and stable hemoglobin
Renal adjust: CrCl <30 mL/min: reduce to 30 mg SC daily. Dialysis: use UFH 5000 units SC q8–12h instead.
Contraindications: Active hemorrhage, platelet count <50,000/mcL, epidural/spinal catheter in situ, recent CNS surgery. Use mechanical prophylaxis (SCDs) until pharmacologic prophylaxis is safe.
Step-by-step management
Acute lower GI bleeding: admission steps
Resuscitate before endoscopy
- Instability or suspected ongoing bleeding: two large-bore IVs; LR 500 mL–1 L bolus, to 2 L total
- Reassess after each bolus; target MAP ≥65 mmHg, HR <100 bpm
Caution: Avoid over-resuscitation in cirrhosis with suspected variceal bleeding.
Transfuse red cells restrictively
- Hemodynamically stable: Hb <7 g/dL
- Coronary disease, ischemia or instability: higher threshold (see text)
Anticoagulants
- Bleeding that needs admission: hold anticoagulants
- Day 1: document the restart plan; resume after bleeding stops
Localize the source
- Ongoing, hemodynamically significant bleeding: CTA first
- Extravasation on CTA: prompt angiography ± embolization
- High suspicion of upper source (melena, BUN/Cr >30): EGD
Colonoscopy after prep: treat bleeding or stigmata
- Diverticular: through‑the‑scope clips, band ligation or coagulation
- Angioectasia: argon plasma coagulation
- Post-polypectomy: through‑the‑scope clips
Bleeding despite endoscopic therapy
- With instability: angiography ± embolization
- Endoscopic and angiographic therapy failed: surgical consult
Tranexamic acid is not recommended.
IV Fluids & Infusions
Fluid resuscitation in acute lower GI hemorrhage prioritizes restoration of effective circulating volume to maintain end-organ perfusion. Crystalloid resuscitation with lactated Ringer solution or normal saline should be initiated immediately through two large-bore (18-gauge or larger) peripheral IV lines. The resuscitation goal is a mean arterial pressure of at least 65 mmHg, heart rate below 100 bpm, and urine output greater than 0.5 mL/kg/hour. Balanced crystalloids such as lactated Ringer solution are preferred over normal saline to reduce the risk of hyperchloremic metabolic acidosis, particularly in patients requiring large-volume resuscitation exceeding 2 liters. In patients with suspected variceal hemorrhage and known cirrhosis, avoid aggressive over-resuscitation as this may increase portal pressure and exacerbate bleeding. Although most patients with LGIB on warfarin are unlikely to require reversal, reversal is suggested for a life-threatening LGIB with an INR substantially exceeding the therapeutic range and recommended in hemodynamic instability, with 4-factor PCC preferred to fresh frozen plasma; cryoprecipitate is indicated when fibrinogen falls below 150 mg/dL. Massive transfusion protocol activation should be considered when hemodynamic instability persists despite initial resuscitation.
- Establish two large-bore IV lines (18G or larger) — antecubital preferred for rapid infusion B
- Lactated Ringer solution 500 mL–1 L IV bolus over 15–30 minutes; repeat up to 2 L total as initial resuscitation
- If LR unavailable, use Normal Saline (0.9% NaCl) 500 mL–1 L IV bolus at same rate
- After initial resuscitation, switch to maintenance: LR or NS at 125 mL/h, titrate to hemodynamic goals
- GoLYTELY (PEG-3350 with electrolytes) 4 L reconstituted solution — chill for palatability
- Administer 240 mL (8 oz) PO or via NG tube every 10 minutes until 4 L consumed (target 3–4 hours total)
- Pre-medicate with ondansetron 4 mg IV 30 minutes before starting prep to reduce nausea
- Patient must remain NPO except for prep solution; keep head of bed elevated ≥30 degrees to prevent aspiration
- Activate MTP via blood bank — trigger: ongoing hemodynamic instability despite initial resuscitation
- Platelets: maintain a platelet count of >30 × 109/L in severe LGIB; a higher threshold of >50 × 109/L can be considered if endoscopic procedures are required; no routine platelet transfusion for patients on antiplatelets. For warfarin reversal, 4-factor PCC is preferred to FFP.
- Administer via rapid infuser/blood warmer through large-bore access; calcium gluconate 1 g IV per 4 units to prevent citrate toxicity
- Check CBC, PT/INR, fibrinogen, ionized calcium after every 6 units pRBC; target fibrinogen >150 mg/dL (give cryoprecipitate 10 units if low)
Conditional Orders
Conditional orders define the clinical decision pathways that guide nursing and physician responses to evolving patient status. Each condition specifies a measurable trigger threshold paired with a concrete intervention. These orders enable rapid response to the most critical complications of acute lower GI hemorrhage, including hemodynamic deterioration, refractory bleeding requiring interventional radiology, and transfusion-related complications. All conditional orders should be reviewed and reaffirmed every 12 hours by the attending physician, and any triggered condition should prompt immediate notification to the covering medical team for reassessment of the overall management plan.
- Optimal timing of colonoscopy in acute LGIB: urgent (<24h) vs. elective (>24h) timing remains debated, with recent trials showing no significant mortality difference
- Role of CT angiography as first-line diagnostic modality before colonoscopy in hemodynamically stable patients with moderate bleeding
- Optimal timing for anticoagulation reinitiation after hemostasis — typically 24–72 hours but highly individualized based on thrombotic risk
- Tranexamic acid in GI bleeding: HALT-IT trial showed no mortality benefit and potential increased thromboembolic risk; not currently recommended
Step-Down & Discharge
Step-down from ICU or monitored bed to general ward should occur when hemodynamic stability has been maintained for at least 12 hours without vasopressor support, the hemoglobin has stabilized with no transfusion requirement in the preceding 24 hours, and the patient demonstrates clinical evidence of cessation of hemorrhage. Discharge planning should incorporate colonoscopy findings, pathology results, anticoagulation reinitiation decisions, and appropriate outpatient follow-up with gastroenterology within 2 to 4 weeks. Patients discharged on new or modified medications require comprehensive medication reconciliation and clear written instructions regarding warning signs that should prompt immediate return to the emergency department.
Step-Down to Ward Criteria
- Hemodynamically stable for ≥12 hours (MAP ≥65 mmHg, HR <100 bpm) without vasopressors or ongoing fluid boluses
- Hemoglobin stable (<1 g/dL drop in 12 hours) with no transfusion requirement in preceding 24 hours
- No active hematochezia for ≥12 hours; stools transitioning to brown or formed
- Tolerating clear liquid diet without nausea, vomiting, or abdominal distension
- Lactate normalized (<2 mmol/L) or trending downward on serial measurements
Discharge Criteria
- No rectal bleeding for ≥24 hours with stable hemoglobin on two consecutive measurements 12 hours apart
- Tolerating regular diet with adequate oral intake for ≥24 hours without GI symptoms
- Colonoscopy completed with definitive source identified and treated (if source found) or negative workup with stable hemoglobin
- Anticoagulation plan documented: reinitiation timing, dose, and follow-up INR or anti-Xa schedule established with primary team
- Patient and family education completed regarding: warning signs for recurrent bleeding (bright red blood per rectum, dizziness, syncope), dietary modifications, medication changes, and when to return to ED
- Outpatient gastroenterology follow-up scheduled within 2–4 weeks; PCP follow-up within 1 week for CBC recheck
Discharge Medications
| Drug | Dose | Duration | Follow-up Labs |
|---|---|---|---|
| Pantoprazole (Protonix) | Pantoprazole 40 mg PO daily | 4–8 weeks (if upper source not excluded or concurrent ulcer) | None routine; reassess need at GI follow-up |
| Ferrous sulfate (Feosol) | Ferrous sulfate 325 mg PO daily on empty stomach | 8–12 weeks (until Hb normalized) | CBC + reticulocyte count at 4 weeks; ferritin + iron studies at 8 weeks |
| Enoxaparin or warfarin (if applicable) | Resume anticoagulant at prior dose per hematology/cardiology plan | Per original indication; typical reinitiation 24–72h post-hemostasis | INR in 3–5 days (warfarin); CBC at 1 week; anti-Xa if LMWH dose uncertainty |
| Docusate sodium (Colace) | Docusate sodium 100 mg PO BID | 2–4 weeks (avoid straining) | None; discontinue when stools normalized |
You were admitted for bleeding from your lower intestine (colon). You were given IV fluids and, if needed, blood transfusions to restore your blood levels. You received a bowel preparation drink to clean your colon, followed by a colonoscopy to find and treat the source of bleeding. Your bleeding has now stopped and your blood counts are stable.
At discharge, please take your prescribed medications as directed, including iron supplements to rebuild your blood levels and a stomach-protecting medication. Watch for warning signs: bright red blood from the rectum, black tarry stools, dizziness, lightheadedness, or fainting. If any of these occur, go to the nearest emergency department immediately. Follow up with your gastroenterologist in 2 to 4 weeks and your primary care doctor within 1 week for a blood count recheck.
Quick Reference Card
Protocol Experience: Where the Order Set Slips and How Seasoned Clinicians Adjust
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Experienced practitioners have come to view the standard LGIB order set as a starting framework that needs three or four specific deviations on every patient to match contemporary evidence. The bundles that fail most consistently are the empiric proton-pump-inhibitor reflex, the over-transfusion despite hemodynamic stability, and the delayed anticoagulant-resumption plan that produces avoidable thrombotic complications during the recovery period.
Where Bundles Slip in Practice
The most consistent order set drift experienced clinicians see is the reflexive empiric proton pump inhibitor for any GI bleeding — appropriate for upper GI bleeding suspicion but not for documented lower GI bleeding. They now hold PPI for LGIB admissions unless there is clinical or laboratory evidence of an upper source (melena, BUN/creatinine ratio over 30, hematemesis history). The over-transfusion pattern — chasing hemoglobin above 8 even in hemodynamically stable non-cardiac patients — is the second consistent drift, and restrictive transfusion at hemoglobin under 7 (under 8 in active cardiac disease) is the evidence-aligned threshold.
Re-Assessment Rhythm
Vital signs every hour for the first 8 hours, then every 2 hours through hour 24, with serial hemoglobin every 4 hours during the first 24 hours. The Oakland score is recalculated every 12 hours during the first 48 hours because the trajectory matters more than the admission value. A patient whose Oakland score rises during admission is rebleeding silently and needs CT angiography rather than another unit of PRBC. The trend, not the snapshot, is what drives the escalation decisions.
Escalation Tripwire
Persistent tachycardia after 2 units of packed red blood cells plus 2 L of lactated Ringer’s resuscitation, OR a hemoglobin that remains under 8 despite transfusion, OR any new hypotension, triggers immediate CT angiography rather than continuing to transfuse blindly. The conventional wisdom of “transfuse and reassess” produces preventable mortality in actively bleeding patients whose source has not been localized, and CTA is more useful than colonoscopy in the hemodynamically unstable patient because it can demonstrate active extravasation that drives interventional radiology embolization.
Anticoagulant Resumption Doctrine
The anticoagulation resumption plan is documented on day 1, not at discharge. For diverticular hemorrhage in atrial fibrillation patients on apixaban or rivaroxaban, restart at therapeutic dose on day 5–7 after bleeding stops if no rebleeding has occurred and colonoscopy has confirmed the source. For warfarin-anticoagulated patients, bridging heparin while INR re-titrates is the standard. The thromboembolic risk of prolonged anticoagulant interruption in high-risk patients (CHA2DS2-VASc ≥4, mechanical valves) exceeds the rebleeding risk after 5–7 days of stable hemostasis.
Illustrative Scenario
A woman in her early seventies with non-valvular atrial fibrillation on apixaban presented with sudden painless large-volume hematochezia. Initial vitals showed blood pressure 102/64 mmHg, heart rate 108 bpm, and hemoglobin 9.4 g/dL. Oakland score was at least 21 (admission indicated). The admitting team had initially ordered empiric pantoprazole 80 mg IV bolus plus 8 mg/hr drip, which the treating clinicians held pending evidence of upper source — BUN/creatinine ratio was 16, no melena history, no hematemesis. Apixaban was held; although the last dose was within 4 hours, andexanet alfa was reserved for a life-threatening bleed that does not respond to initial resuscitation and cessation of the anticoagulant alone. Resuscitation began with 1 L lactated Ringer’s bolus plus 1 unit packed red blood cells; persistent tachycardia at 108 after the first unit triggered urgent CT angiography rather than a second blind PRBC transfusion. CTA showed active extravasation from a sigmoid diverticulum, and interventional radiology performed superselective microcoil embolization within 2 hours of imaging. Hemodynamics stabilized post-embolization. Colonoscopy on hospital day 3 confirmed the embolized sigmoid diverticulum as the source with no additional bleeding stigmata, and apixaban was resumed at therapeutic dose on day 6 without need for chronic PPI therapy.
Practice Protocol Adjustments to the Standard Order Set
- Hold empiric PPI in LGIB admissions unless there is clinical or laboratory evidence of upper GI source (melena, BUN/creatinine ratio over 30, hematemesis history, hemodynamic instability with unclear source). The reflexive PPI for any GI bleed is the order set drift seasoned clinicians correct most often. PPI for documented UGIB only.
- Restrictive transfusion threshold (hemoglobin under 7, under 8 in active cardiac disease) over the older liberal threshold. Over-transfusion in hemodynamically stable patients increases volume overload, transfusion-related complications, and length of stay without survival benefit.
- CT angiography rather than additional transfusion as escalation tripwire for persistent tachycardia after 2 units PRBC plus 2 L LR, hemoglobin still under 8 despite transfusion, or new hypotension. CTA demonstrates active extravasation in hemodynamically unstable patients and drives interventional radiology embolization that blind transfusion will not.
- Day-1 anticoagulant resumption plan documentation, with resumption at day 5–7 for diverticular hemorrhage after stable hemostasis. The thromboembolic risk of prolonged interruption in high-risk patients exceeds the rebleeding risk in this window. Bridging plans and resumption dates belong in the admission note, not discovered at discharge.
Anticoagulant reversal
LGIB on anticoagulants: hold, and when to reverse
Admitted with LGIB: hold the anticoagulant; consult hematology on restart timing.
Warfarin
Reversal
Suggested for a life-threatening bleed with INR well above range; recommended if unstable
Agent
4-factor PCC 25–50 units/kg IV by INR, preferred to FFP, plus vitamin K 10 mg IV
Caution
PCC: thromboembolism risk; contraindicated in DIC or known HIT
Dabigatran
Reversal
Suggested only for a life-threatening bleed despite resuscitation and holding it, last dose within 24 h
Agent
Idarucizumab 5 g IV, when available
Rivaroxaban or apixaban
Reversal
Suggested only for a life-threatening bleed despite resuscitation and holding it, last dose within 24 h
Agent
Andexanet alfa when available (FDA, Dec 18, 2025: risks outweigh benefits; no U.S. sales after Dec 22, 2025)
Caution
Boxed warning: thromboembolic and ischemic events, cardiac arrest, sudden death
Warfarin otherwise: hold it; most need no reversal; routine vitamin K is not suggested.
Frequently Asked Questions
- Upper GI Bleed Admission Order Set: A Comprehensive Clinical Protocol
- Acute Pancreatitis Admission Order Set: Resuscitation, Pain Control, and Nutrition
- Acute Cholangitis Admission Order Set: Antibiotics, Biliary Drainage, and Supportive Care
- Ischemic Colitis: ACG Diagnosis with CT, Colonoscopy Severity Grading, and Conservative versus Surgical Management
- Gastric Subepithelial Tumors: Diagnosis and Management
- Gastroesophageal Reflux Disease (GERD) — Diagnosis and Management
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ACG 2021 Clinical Guideline: Colorectal Cancer Screening (American Journal of Gastroenterology · 2021)
- ACG 2023 Clinical Guideline: Management of Patients With Acute Lower GI Bleeding (American Journal of Gastroenterology · 2022)